Havva Kocayiğit1, Kezban Özmen Süner2, Yakup Tomak1, Gürkan Demir1, Selçuk Yaylacı3, Hamad Dheir4, Ertuğrul Güçlü5, Ali Fuat Erdem1. 1. Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey. 2. Department of Intensive Care, Sakarya University Education and Research Hospital, Sakarya, Turkey. 3. Department of Internal Medicine, Sakarya University Education and Research Hospital, Sakarya, Turkey. 4. Department of Nephrology, Sakarya University Education and Research Hospital, Sakarya, Turkey. 5. Department of Infectious Diseases and Clinical Microbiology, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Abstract
WHAT IS KNOWN AND OBJECTIVES: In November 2019, several patients were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. So far, there are no specific treatments with proven high efficacy in patients with SARS-CoV-2. Presently, several drugs, such as hydroxychloroquine, ribavirin, favipiravir (FVP), lopinavir/ritonavir (LPV/r), remdesivir and oseltamivir, have been suggested as effective treatments for SARS-CoV-2. The aim of this study was to describe the clinical experience with FPV and LPV/r in critically ill patients with COVID-19 at Sakarya University Education and Research Hospital. METHODS: The study included 107 consecutive patients who had a laboratory confirmation of COVID-19 and were admitted to the intensive care unit (ICU) between 19 March and 19 May 2020. Follow-up continued through 30 May 2020 when the last observed patients were discharged. RESULTS AND DISCUSSION: Of the 107 patients, 65 received FPV (Group FPV) and 42 received LPV/r (Group LPV/r). The two groups were similar in terms of demographic data and clinical findings. 43 (66.2%) of the 65 patients in the FPV group and 23 (54.8%) of the 42 patients in the LPV/r group died (p = 0.237). The median ICU stay was 6.6 (IQR, 3-10) days in the FPV group and 9 (IQR, 6-16) days in the LPV/r group, which was a statistically significant difference (p = 0.010). WHAT IS NEW AND CONCLUSION: The length of hospital stay was significantly lower in the FVP group compared to the LPV/r group among patients who were discharged from the ICU. Although the analysis was done with a limited number of patients and the observed difference in mortality rate is of some concern, FVP treatment may be more beneficial than LPV/r in terms of effective use in the ICU.
WHAT IS KNOWN AND OBJECTIVES: In November 2019, several patients were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. So far, there are no specific treatments with proven high efficacy in patients with SARS-CoV-2. Presently, several drugs, such as hydroxychloroquine, ribavirin, favipiravir (FVP), lopinavir/ritonavir (LPV/r), remdesivir and oseltamivir, have been suggested as effective treatments for SARS-CoV-2. The aim of this study was to describe the clinical experience with FPV and LPV/r in critically ill patients with COVID-19 at Sakarya University Education and Research Hospital. METHODS: The study included 107 consecutive patients who had a laboratory confirmation of COVID-19 and were admitted to the intensive care unit (ICU) between 19 March and 19 May 2020. Follow-up continued through 30 May 2020 when the last observed patients were discharged. RESULTS AND DISCUSSION: Of the 107 patients, 65 received FPV (Group FPV) and 42 received LPV/r (Group LPV/r). The two groups were similar in terms of demographic data and clinical findings. 43 (66.2%) of the 65 patients in the FPV group and 23 (54.8%) of the 42 patients in the LPV/r group died (p = 0.237). The median ICU stay was 6.6 (IQR, 3-10) days in the FPV group and 9 (IQR, 6-16) days in the LPV/r group, which was a statistically significant difference (p = 0.010). WHAT IS NEW AND CONCLUSION: The length of hospital stay was significantly lower in the FVP group compared to the LPV/r group among patients who were discharged from the ICU. Although the analysis was done with a limited number of patients and the observed difference in mortality rate is of some concern, FVP treatment may be more beneficial than LPV/r in terms of effective use in the ICU.
Authors: Matteo Bassetti; Silvia Corcione; Silvia Dettori; Andrea Lombardi; Tommaso Lupia; Antonio Vena; Francesco Giuseppe De Rosa; Andrea Gori; Daniele Roberto Giacobbe Journal: Expert Rev Respir Med Date: 2021-05-21 Impact factor: 3.772
Authors: Abbas Al Mutair; Jinan Shamou; Saad Alhumaid; Laila Layqah; Gasmelseed Y Ahmed; Koritala Thoyaja; Mohammed Al Mohaini; Sana Almahmoud; Mazin Barry; Amjad Khan; Kuldeep Dhama; Lamiaa Hamad Al-Jamea; Alxeander Woodman; Ali A Rabaan Journal: J Infect Public Health Date: 2022-02-15 Impact factor: 3.718